ALK and non-small cell lung carcinoma: Other studies have also confirmed that EGFR/ALK mutations in NSCLC models upregulate PD‐L1 expression by activating the PI3K‐AKT, MEK (Mitogen‐activated protein kinase kinase)/ERK(Extracellular signal‐regulated kinase) pathway.155